New future for Italian oncology and neurology centres:
This article was originally published in Clinica
Italy's flagship oncology centre, the National Tumour Institute (INT), may be sold to the state insurance group Inail, in a transaction that promises renewed investment in its facilities. Talks are underway for Inail to buy and lease the Milan-based buildings at a favourable rate that would enable the INT to settle debts that "threaten its very survival and hinder its relaunch and development", said the health ministry. Similar negotiations are underway with Inail, the body responsible for Italy's obligatory work-related health and safety insurance, regarding the forthcoming development of the new Carlo Besta Neurology Institute, relocated within Milan.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.